Serum levels of glial fibrillary acidic protein and Nogo-A in children with autism spectrum disorders.
Improved biomarkers would facilitate the diagnosis and treatment of autism spectrum disorders (ASD). Our objective was to examine the levels of Nogo-A and glial fibrillary acidic protein (GFAP) in children with ASD. Serum concentrations of GFAP and Nogo-A were determined by enzyme-linked immunosorbent assay. In this preliminary study, we found that serum Nogo-A was not found significantly different between groups, while serum levels of GFAP were significantly lower in ASD than controls. It will be of great interest to determine other potential causes of elevated serum levels of GFAP, and whether this elevation has any phenotypic effect.